ArticleBMC psychiatry2025
Utilizing resting motor threshold to predict cognitive function in drug-naive patients with major depressive disorder.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunotherapy for depression: targeting cytokine pathways in major depressive disorder.Psychopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) is a common and disabling condition associated with significant cognitive impairments that persist over the long term, affecting patients' social function. Traditional cognitive testing methods are time-consuming and subjective. This study investigates whether resting motor threshold (RMT), a neurophysiological measure of motor cortical excitability, can predict cognitive function in drug-naive patients with MDD, with a focus on sex-specific differences.
methodsThis cross-sectional study enrolled 158 first-episode, drug-naive patients with MDD from August 2023 to April 2024. Participants underwent comprehensive cognitive assessments using the MATRICS Consensus Cognitive Battery (MCCB) and transcranial magnetic stimulation (TMS) to measure RMT. Hormone levels were also assessed. The study was approved by the hospital's Ethics Committee and conducted in accordance with the Declaration of Helsinki. Statistical analysis included bivariate correlation and multiple regression analyses to identify factors associated with cognitive function.
resultsA total of 138 subjects completed the study. The mean age was 19.28 ± 6.84 years, with 41 males (29.7%) and 97 females (70.3%). In the overall sample, higher right RMT was associated with better attention/vigilance (CPT-IP) performance. In male patients, higher left RMT was associated with lower verbal learning (HVLT-R) scores, while higher right RMT was associated with higher HVLT-R scores. No significant correlations were found in female patients. Multiple regression analyses showed that these relationships were independent of age, education, and hormone levels.
conclusionsThis exploratory study is the first to demonstrate that RMT can predict verbal learning ability, attention, and vigilance in male patients with MDD, whereas no significant correlation was observed in female patients. This finding reveals RMT's potential significance and highlights that sex differences necessitate consideration when developing rTMS-based treatment regimens targeting both antidepressant and cognitive outcomes. Further longitudinal studies with larger sample sizes are needed to validate its clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.